Insider · CIK 0001414815
Martin Mackay
Files at CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.), RLYB (Rallybio Corp), SWTX (SpringWorks Therapeutics, Inc.), KLRA (Kailera Therapeutics, Inc.). First filing -, latest -.
Martin Mackay files SEC Form 4 as director at CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.), and also at RLYB (Rallybio Corp), SWTX (SpringWorks Therapeutics, Inc.), KLRA (Kailera Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Martin Mackay has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Common Stock | +1,438 | $177.62 | $255k | 15,730 | May 11, 2026 |
| May 8, 2026 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Common Stock | +1,407 | $177.62 | $250k | 17,137 | May 11, 2026 |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
| Feb 18, 2026 | RLYB Rallybio Corp | AGrant or award Option (Right to Buy)derivative | +18,055 | $3.60 | $65k | 18,055 | Feb 20, 2026 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Common Stock | -20,023 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -29,445 | - | - | 0 | Jul 2, 2025 |
| May 21, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Common Stock | +946 | $134.98 | $128k | 13,477 | May 23, 2025 |
| May 21, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Common Stock | +815 | $134.98 | $110k | 14,292 | May 23, 2025 |
| May 21, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Stock Options (Right to Buy)derivative | +2,076 | $134.98 | $280k | 2,076 | May 23, 2025 |
| May 14, 2025 | SWTX SpringWorks Therapeutics, Inc. | AGrant or award Common Stock | +10,060 | $0.00 | $0 | 20,023 | May 15, 2025 |
| May 13, 2025 | RLYB Rallybio Corp | AGrant or award Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | May 15, 2025 |
Questions about Martin Mackay
Answered from the filings on this page, as of the latest one.
Is Martin Mackay buying or selling?
Martin Mackay has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Martin Mackay's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Martin Mackay has 0.
Where does Martin Mackay file Form 4?
Martin Mackay has filed Form 4 at CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.); RLYB (Rallybio Corp); SWTX (SpringWorks Therapeutics, Inc.); KLRA (Kailera Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.